Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy

被引：2
|
作者：
Shakiba, Yasmin [1 ,2 ]
Vorobyev, Pavel O. O. [2 ]
Mahmoud, Marah [2 ]
Hamad, Azzam [2 ]
Kochetkov, Dmitriy V. V. [2 ]
Yusubalieva, Gaukhar M. M. [2 ,3 ,4 ]
Baklaushev, Vladimir P. P. [2 ,3 ,4 ]
Chumakov, Peter M. M. [2 ]
Lipatova, Anastasia V. V. [2 ]
机构：
[1] Moscow Inst Phys & Technol, Dolgoprudnyi 141701, Moscow Region, Russia
[2] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia
[3] Fed Med Biol Agcy FMBA, Fed Res Clin Ctr Specialized Med Care & Med Techno, Moscow 115682, Russia
[4] Fed Ctr Brain Res & Neurotechnol FMBA Russia, Moscow 117513, Russia
来源：
BIOCHEMISTRY-MOSCOW | 2023年 / 88卷 / 06期
基金：
俄罗斯科学基金会;
关键词：
oncolytic virus; recombinant virus; immunosuppression; immunomodulation; cytokine; vaccinia virus; COLONY-STIMULATING FACTOR; IMMUNOGENIC CELL-DEATH; GM-CSF; TUMOR-REGRESSION; IMMUNE-RESPONSE; CTLA-4; BLOCKADE; DOUBLE GENES; T-CELLS; PROTEIN; INTERLEUKIN-10;
D O I：
10.1134/S000629792306010X
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Cancer virotherapy is an alternative therapeutic approach based on the viruses that selectively infect and kill tumor cells. Vaccinia virus (VV) is a member of the Poxviridae, a family of enveloped viruses with a large linear double-stranded DNA genome. The proven safety of the VV strains as well as considerable transgene capacity of the viral genome, make VV an excellent platform for creating recombinant oncolytic viruses for cancer therapy. Furthermore, various genetic modifications can increase tumor selectivity and therapeutic efficacy of VV by arming it with the immune-modulatory genes or proapoptotic molecules, boosting the host immune system, and increasing cross-priming recognition of the tumor cells by T-cells or NK cells. In this review, we summarized the data on bioengineering approaches to develop recombinant VV strains for enhanced cancer immunotherapy.
引用
收藏
页码：823 / 841
页数：19
相关论文
共 50 条
  • [31] ANTIGENIC PROPERTIES OF VACCINIA VIRUS AND OF THE VIRUS RECOMBINANT STRAINS EXPRESSING HETEROLOGOUS GENES
    CHELYAPOV, NV
    ANTONOVA, TP
    YANOVA, NN
    CHERNOS, VI
    ACTA VIROLOGICA, 1988, 32 (05) : 409 - &
  • [32] Oncolytic Virus Immunotherapy
    Marchini, Antonio
    Ilkow, Carolina S.
    Melcher, Alan
    CANCERS, 2021, 13 (15)
  • [33] Visualization of cancer therapy in preclinical tumor models and in human cancer patients treated with light emitting oncolytic vaccinia virus strains
    Szalay, Aladar A.
    LUMINESCENCE, 2014, 29 : 46 - 47
  • [34] Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy
    Kochneva, Galina
    Sivolobova, Galina
    Tkacheva, Anastasiya
    Grazhdantseva, Antonina
    Troitskaya, Olga
    Nushtaeva, Anna
    Tkachenko, Anastasiya
    Kuligina, Elena
    Richter, Vladimir
    Koval, Olga
    ONCOTARGET, 2016, 7 (45) : 74171 - 74188
  • [35] Immunotherapeutic potential of oncolytic vaccinia virus
    Thorne, Steve H.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [36] Effectiveness of different oncolytic vaccinia virus strains for the in vitro and in vivo treatment of peritoneal mesothelioma
    Yurttas, Can
    Beil, Julia
    Susanne, Berchtold
    Smirnow, Irina
    Kloker, Linus D.
    Sipos, Bence
    Koenigsrainer, Alfred
    Mihaljevic, Andre
    Lauer, Ulrich
    Thiel, Karolin
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 146 - 146
  • [37] Theranostic Potential of Oncolytic Vaccinia Virus
    Rojas, Juan J.
    Thorne, Steve H.
    THERANOSTICS, 2012, 2 (04): : 363 - 373
  • [38] Immunotherapeutic potential of oncolytic vaccinia virus
    Steve H. Thorne
    Immunologic Research, 2011, 50 : 286 - 293
  • [39] Oncolytic vaccinia virus: a silver bullet?
    Lusky, Monika
    Erbs, Philippe
    Foloppe, Johann
    Acres, R. Bruce
    EXPERT REVIEW OF VACCINES, 2010, 9 (12) : 1353 - 1356
  • [40] Immunotherapeutic potential of oncolytic vaccinia virus
    Thorne, Steve H.
    IMMUNOLOGIC RESEARCH, 2011, 50 (2-3) : 286 - 293
12345